Argatroban Articles
Hikma adds to stake in Promopharm; gets US appro for argatroban
22 January 2012
Jury finds against Pfizer, calling for $142M in damages for drug fraud; Teva gets tentative OK for generic Argatroban
26 March 2010
Barr Labs challenges Argatroban patent
7 January 2008
480B yen sales target for Mitsubishi Tanabe
28 May 2007
Biovitrum's FY 2006 net profit plummets 47.4%
5 March 2007
Japan stock market week to July 25
1 August 2005
Japan's second-tier drugmakers losing out
11 April 2005
Positive results for Medicure's novel antithrombotic
7 March 2005
Texas Biotech aligned behind new strategy
8 July 2002
Argatroban OKed for new use in USA
15 April 2002
Texas Biotech announces financial loss
4 March 2002
Texas Biotech announces initiation of Ph II argatroban trial
11 October 2001
Texas gets approvable letter for Argatroban sNDA
23 July 2001
Texas, SB seek new Acova indication
21 December 2000
First launch for SmithKline Beecham's argatroban in HIT
15 November 2000
SB and Texas gain US backing for agatroban
3 July 2000
Texas Biotechnology Corp issuing 5 million shares
11 April 2000
Texas' Novastan is "approvable," says FDA
24 February 2000
Texas submits corrected amendment to Novastan NDA
26 August 1999
Texas resubmits Novastan to FDA
29 March 1999
Sanofi-Synthelabo Merger Strong In Cardio, CNS
10 December 1998
FDA Rejects The Medicine Company's Hirulog
29 October 1998
Synthelabo Pipeline
15 October 1998
Texas' Novastan Is "Non-Approvable"
14 May 1998
SB Defends Independence On Strong R&D Grounds
23 April 1998
Argatroban In Acute Myocardial Infarction
8 April 1998
Synthelabo Predicts Strong Opportunities For Growth
6 April 1998
UK Launch For Refludan; Angina Filing By End-98?
19 March 1998
Product News In Brief
29 January 1998
Synthelabo's "Excellent" Year; Will Acquire Firm
21 October 1997
New Studies At European Cardiology Meeting
15 September 1997
Texas' Novastan Granted Expedited Review
10 September 1997
SB To Market Novastan In North America
7 August 1997
Six-Month Sales Up 12.4% at Synthelabo
29 July 1997
Texas Files NDA For Novastan
9 July 1997
Texas Reveals Positive Ph III Novastan Data
23 April 1997
Synthelabo Presents 1996 Highlights, New Research
21 April 1997
Ph II Data With Texas' Novastan In Acute MI
7 April 1997
First Phase II Data With Argatroban In AMI
28 October 1996
Synthelabo Pipeline Supports "Seven Key Product" Strategy
21 October 1996
Argatroban Gets Stroke Indication In Japan
24 June 1996
Texas Biotech / Synthelabo : Novastan news
29 January 1996
Good Performance Forecast For Euro Drugmakers
26 June 1995
Synthelabo Reports On New Products
17 April 1995
Daiichi Sales "Exceeding Targets"
30 January 1995
TEXAS BIOTECH STOCK OFFERING
6 December 1993
SYNTHELABO EXPECTS 23% RISE IN '93 PROFITS
25 October 1993
TEXAS BIOTECH IN ALLIANCE
23 August 1993
SYNTHELABO TAKES ON EUROPEAN DIMENSION
26 July 1993
GENENTECH AND TEXAS BIOTECH DEAL
5 July 1993
HYUN DAI TO LICENSE NOVASTAN INJ
7 June 1993
SYNTHELABO RESEARCH AND DEVELOPMENT
12 April 1993
SYNTHELABO GAINS NOVASTAN RIGHTS
25 January 1993
EUROPE STOCK COMMENT
4 January 1993
SYNTHELABO LICENSING DEAL
4 January 1993
Showing 1-59 of 59 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
